Introduction {#S1}
============

Gastric cancer (GC) remains a leading cause of cancer-related mortality in the United States ([@B4]) and China ([@B5]). Because GC is mostly asymptomatic until it progresses to advanced stages, and lacking of an efficient biomarker with high sensitivity and specificity, the prognosis of GC patients remains poor. Hence, there is an urgent need to discover novel non-invasive biomarkers for the early diagnosis of GC.

Exosomes are 30--100 nm diameter, membrane-enclosed vesicles that are secreted by numerous cell types and present in various body fluids, such as blood, urine, saliva, etc. ([@B22]). Exosomes act as mediators in intercellular communications by transporting proteins, lipids and nucleic acids to recipient cells, resulting in the modulation of different processes such as tumor invasion, angiogenesis, metastasis, and chemoresistance ([@B16]; [@B10]). The features of quick detection, convenient collection and minimal pain make exosomes serve as an ideal liquid biopsy tool for clinical application ([@B7]; [@B2]; [@B26]). MicroRNAs (miRNAs) are small non-coding RNAs (18--24 nt) that regulate protein translation. Extracellular miRNAs can be packaged into exosomes, which protects them from digestion by RNases ([@B21]). High stability and enrichment of circulating exosomal miRNAs offer an attractive option for cancer diagnosis and prognosis. For example, serum exosomal miR-1246 and miR-21 could be used as promising diagnostic biomarkers for pancreatic cancer ([@B20]; [@B18]), prostate cancer ([@B3]), and hepatocellular carcinoma ([@B27]). To date, the majority of efforts are focused on breast cancer, prostate cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma, and lung cancer ([@B15]). However, the relevance of serum exosomal miRNAs in early-stage GC has not been clearly elucidated.

We previously established an optimized procedure for screening and validating serum exosomal RNA biomarkers in prostate cancer and colorectal cancer ([@B11]; [@B32]). In this study, we used next-generation sequencing (NGS) to identify differential miRNA signatures in exosomes isolated from serum of early-stage GC patients, and provide a non-invasive method for early-stage GC detection. Finally, real-time qRT-PCR verified that the expression levels of exosomal miR-92b-3p, -146b-5p, -9-5p, and let-7g-5p were significantly higher in early-stage GC by comparison with matched healthy individuals, which established their utility as potential early-stage GC biomarkers.

Materials and Methods {#S2}
=====================

Patients and Samples {#S2.SS1}
--------------------

Serum samples were obtained from early-stage GC patients and healthy individuals at the Harbin Medical University Cancer Hospital between 2015 and 2016. The screening cohort included 36 early-stage GC patients, and 12 age and gender-matched healthy individuals. Fifty pairs of newly recruited early-stage GC patients and matched healthy individuals were included in the validation cohort. All serum samples were taken before treatment. All patients were histopathologically confirmed as gastric non-cardia adenocarcinoma patients (stages I and II) after operation. Clinical information including age, gender, pathological differentiation, pathological tumor stage, tumor invasion depth, presence of lymph node metastases, WHO cohesiveness, carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199) levels, and nerve infiltration were collected from medical records. The pathological tumor stage was identified according to the seventh edition AJCC TNM classification. CEA and CA199 levels were obtained from routine blood test before surgery, and CEA \> 5 ng/ml and CA199 \> 37 U/ml were defined as high levels. Inclusion criteria for healthy individuals, who were used as normal controls, included no malignancy, autoimmune disorders, endocrine disease, hepatitis, or HIV infection. The studies have been performed in accordance with the Declaration of Helsinki. All participants gave written informed consent, and the Harbin Medical University Cancer Hospital Ethics Committee approved the study. The overview flowchart of this study is shown in [Figure 1A](#F1){ref-type="fig"}, and patient data are summarized in [Table 1](#T1){ref-type="table"}. Total 5 ml venous blood samples were collected before initial treatment, and was centrifugated at 3000 *g* for 10 min at 4°C within 2 h after collection. The supernatant (serum) was then transferred to RNase/DNase-free tubes and stored at −80°C until further processing.

![Schematic flowchart of the analytical pipeline and the results based on the next-generation sequencing (NGS). **(A)** Schematic flowchart of identification of early-stage gastric cancer (GC)-specific exosomal miRNAs. **(B)** RNA biotypes in the small RNA library prepared from human serum exosomes. Pie chart showing the mean percentage reads of serum exosomal small RNA library. Raw reads were the sequences obtained by RNA sequencing (RNA-seq). Clean reads were generated after read filtering and adapter trimming. Mappable reads were the RNA-seq reads mapped to known human RNAs, and were sorted into the following small ncRNAs: micro RNA (miRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), and transfer RNA (tRNA). **(C)** Venn diagram showing overlap of the differentially expressed miRNAs between stage I gastric cancer vs. healthy individuals (stage I vs. N) and stage II gastric cancer vs. healthy individuals (stage II vs. N). **(D)** Venn diagram showing overlap of the differentially expressed miRNAs in all four stages (stages IA, IB, IIA, and IIB) vs. healthy individuals (N).](fgene-11-00237-g001){#F1}

###### 

Clinicopathological features of early-stage gastric cancer patients in screening and validating cohort.

  Variables                          Screening cohort (%)   Validating cohort (%)   *p*-Value
  ---------------------------------- ---------------------- ----------------------- -----------
  Total number                       36                     50                      
  Age (mean ± SD)                    56.50 ± 9.87           58.10 ± 10.41           0.557
  **Gender**                                                                        
  Female                             11 (30.5)              12 (24.0)               0.622
  Male                               25 (69.5)              38 (76.0)               
  **Pathological differentiation**                                                  0.125
  Poor                               22 (61.1)              21 (42.0)               
  Moderate + Well                    14 (38.9)              29 (58.0)               
  **Invasion depth**                                                                0.986
  T1                                 11 (30.5)              16 (32.0)               
  T2                                 10 (27.8)              14 (28.0)               
  T3                                 15 (41.7)              20 (40.0)               
  **Lymph nodes metastasis**                                                        0.374
  Negative                           29 (80.5)              44 (88.0)               
  Positive                           7 (19.5)               6 (12.0)                
  **TNM stage**                                                                     0.782
  IA                                 11 (30.5)              15 (30.0)               
  IB                                 10 (27.8)              15 (30.0)               
  IIA                                8 (22.2)               14 (28.0)               
  IIB                                7 (19.5)               6 (12.0)                
  **Poorly cohesive**                                                               0.045
  Negative                           17 (47.2)              35 (70.0)               
  Positive                           19 (52.8)              15 (30.0)               
  **Nerve infiltrate**                                                              1
  Negative                           21 (58.3)              30 (60.0)               
  Positive                           15 (41.7)              20 (40.0)               
  **CEA**                                                                           0.694
  Normal                             34 (94.4)              45 (90.0)               
  High                               2 (5.6)                5 (10.0)                
  **CA199**                                                                         0.419
  Normal                             35 (97.2)              50 (100.0)              
  High                               1 (2.8)                0 (0.0)                 

Exosome Isolation {#S2.SS2}
-----------------

Exosomes were isolated using the ExoQuick exosome precipitation solution (System Biosciences, Mountain View, CA, United States) according to the manufacturer's instructions with slight modifications. Briefly, 300 μl of cell-free serum samples were mixed with 75 μl of ExoQuick solution and RNase A (Sigma, St. Louis, MO, United States) to a final concentration of 10 μg/ml. The mixture was kept at 4°C overnight. Afterward, murine RNase inhibitor (NEB, Ipswich, MA, United States) was added to the mixture (150 units/ml) before centrifugation at 1500 *g* for 30 min. Finally, the supernatants were aspirated and the pelleted exosomes were re-suspended in 50 μl 1 × PBS, and immediately used for RNA extraction.

Exosomal RNA Extraction and RNA Library Preparation {#S2.SS3}
---------------------------------------------------

RNA of exosomes was isolated using miRNeasy micro kit (Qiagen, Valencia, CA, United States) according to the manufacturer's protocol. The extracted RNA was eluted with 14 μl of RNase-free water. The library preparation was based on the protocols of Multiplex Small RNA Library Prep Set for Illumina (NEB, Ipswich, MA, United States) as previously described ([@B12], [@B11]). Total 2 ng of isolated RNA was reverse-transcribed into cDNA sequencing libraries. Twelve sequencing libraries with different indices were pooled at a final amount of 2 nM and subjected to DNA sequencing.

Sequencing Data Analysis {#S2.SS4}
------------------------

Next-generation sequencing was carried out on an Illumina HiSeq2000 platform by Novogen, Inc. (Beijing, China). The clustering of the index-coded samples was performed on a cBot Cluster Generation System using TruSeq SR Cluster kit v3-cBot-HS (Illumina). After cluster generation, the libraries were sequenced and 50 bp single-end reads were generated. Clean data were obtained by processing raw data in FASTQ format through custom perl and python scripts. Clean reads with certain range of length were mapped to reference sequence using Bowtie from miRBase (Release 20) and NCBI human genome reference sequences. The softwares miREvo and mirdeep2 were integrated to predict novel miRNA from the clean data. The DESeq R package (version 1.8.3) was used to identify differential expression of miRNAs between two groups. The *p*-values was adjusted using the Benjamini & Hochberg method. Corrected *p*-value of 0.05 was set as the threshold for significantly differential expression by default. To make the sequencing profiles comparable, we normalized RNA profiles as read count of a target RNA per million mapped reads (RPM).

Real-Time Quantitative RT-PCR and Data Normalization {#S2.SS5}
----------------------------------------------------

Some of the differentially expressed miRNAs identified by sequencing were validated using miScript SYBR Green PCR kit (Qiagen, Valencia, CA, United States). MiR-9-5p, let-7g-5p, let-7c-5p, miR-146b-5p, miR-101-3p, miR-92b-3p, miR-21-5p, and miR-26a-5p (MS00010752, MS00008337, MS00003129, MS00003542, MS00008372, MS00032144, MS00009079, MS00029239; Qiagen, Valencia, CA, United States) were selected. MiR-30e-5p (MS00009401; Qiagen, Valencia, CA, United States) was selected as the endogenous normalization control based on our previous study ([@B11]). Briefly, 4 ng of total serum exosomal RNA was reverse-transcribed into cDNA in a 20 μl reaction using the miScript II RT kit (Qiagen, Valencia, CA, United States), followed by dilution of the cDNA products for subsequent real-time PCR reactions. Then, the quantitative PCR was carried out on LightCycler^®^ 480 Real-Time PCR System (Roche Diagnostics, Mannheim, Germany) in a 384-well plate. The PCR reactions were set as follows: 95°C for 15 min, 40 cycles of 94°C for 15 s, 55°C for 30 s, and 72°C for 30 s. All quantitative experiments were independently repeated at least three times to remove any outliers.

Data Processing and Statistical Analysis {#S2.SS6}
----------------------------------------

Cycle threshold (Ct) values, obtained from real-time qPCR, were calculated as the expression data for miRNAs. ΔCt values were analyzed directly to compare different exosomal miRNA transcription levels ([@B25]). ΔCt = Ct~target\ miRNA~ -- Ct~miR--30e--5*p*~, and lower ΔCt values indicated higher expression levels of exosomal miRNAs. Fold change (FC) was based on FC = 2^--ΔΔ*Ct*^, and represented as follows: if FC \> 1, true FC = FC and if FC \< 1, true FC = −1/FC. The subsequent statistical analyses were performed using GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA, United States) and SPSS software version 20.0 (IBM, Corp., Armonk, NY, United States). Data were presented as the mean ± SD. Unpaired Student's *t*-test was used to analyze the differences in miRNA expression between early-stage GC patients and healthy individuals. Receiver operating characteristic (ROC) curve was used to evaluate the diagnostic power of the candidate exosomal miRNAs for early-stage GC. The cut-off value was determined using the Youden Index. Logistic regression adjusted for sex and age was utilized to establish the combination of exosomal miRNAs for GC diagnosis, so did the combined models based on exosomal miRNAs and traditional biomarkers. The performance of the combined models was evaluated by the area under the ROC curves (AUC). A two-sided *p* \< 0.05 was considered statistically significant.

Results {#S3}
=======

Mapping of RNA Sequencing {#S3.SS1}
-------------------------

The average raw reads from the RNA sequencing libraries were about 13 million, from which approximately 12.5 million (96.66%) reads with certain range of length (clean reads) were received after trimming. Among these, about 6.5 million reads (50.20%) were mapped to known RNA species. We annotated the mapped reads into the following biotypes of small ncRNAs: miRNAs, ribosomal RNAs (rRNAs), small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), and transfer RNAs (tRNAs). Analysis of the mapped reads revealed miRNAs were the most common, accounting for 73.38% of all mappable RNAs, followed by 17.10% rRNAs, 8.83% snRNAs, 0.65% snoRNAs, and 0.04% tRNAs ([Figure 1B](#F1){ref-type="fig"}). The raw sequencing data have been deposited in the Gene Expression Omnibus database (accession number: [GSE130654](GSE130654)).

Exosomal MiRNA Profiling in the Screening Stage {#S3.SS2}
-----------------------------------------------

Next, to identify candidate serum exosomal miRNAs for early-stage GC diagnosis, miRNAs with log2 transformed read counts \< 5 and *p* \> 0.05 were removed from the RNA sequencing data. A total of 79 known miRNAs remained after the initial screening step, including 66 up-regulated and 13 down-regulated miRNAs compared to normal control. Further systematic evaluation on the differential expression of the remaining miRNAs using Venn diagrams ([Figure 1C](#F1){ref-type="fig"}) revealed that 23 miRNAs were significantly aberrant in both stage I and stage II GC when compared with normal control ([Supplementary Table S1](#DS1){ref-type="supplementary-material"}), 11 were uniquely found between stage I GC and normal control, and 45 miRNAs between stage II GC and normal control. When the early stage GC was further stratified into stages IA, IB, IIA, and IIB, miR-9-5p, let-7g-5p, and let-7c-5p were the only three miRNAs significantly aberrant in all early stages of GC, and miR-146b-5p was significantly aberrant in stages IA, IIA and IIB, but not in stage IB ([Figure 1D](#F1){ref-type="fig"}). Meanwhile, many serum exosomal miRNAs were differentially expressed in a unique stage, suggesting the complexity of the miRNA transcriptome in tumorigenesis of GC. For example, miR-21-5p and miR-26-5p were significantly aberrant in stage IIB.

To assess the diagnostic value of the aberrantly expressed miRNAs, we performed ROC analysis based on the expression levels of the miRNAs. The miRNAs with *p* \< 0.05, AUC ≥ 0.75, and both sensitivity and specificity at least ≥ 60% were selected as potential candidates for diagnostic markers. After screening, we selected eight serum exosomal miRNAs for downstream validation ([Table 2](#T2){ref-type="table"}).

###### 

Diagnostic efficiencies of serum exosomal miRNA candidates in early-stage gastric cancer.

  Column ID     AUC     *p*-Value   Cut-off   Sensitivity %   Specificity %
  ------------- ------- ----------- --------- --------------- ---------------
  miR-9-5p      0.920   \<0.0001    \>11.36   80              90.91
  let-7g-5p     0.850   0.0005      \>11.42   74.29           90.91
  let-7c-5p     0.886   0.0001      \>12.03   80              90.91
  miR-146b-5p   0.784   0.0048      \>8.705   71.43           81.82
  miR-92b-3p    0.788   0.0304      \>13.04   66.67           90.91
  miR-101-3p    0.805   0.0057      \>10.28   75              90.91
  miR-21-5p     1.000   0.0005      \>12.35   100             90.91
  miR-26a-5p    0.961   0.0013      \>12.96   85.71           90.91

AUC, area under the receiver operating characteristic curve.

Evaluation of the Diagnostic Potential of Exosomal MiRNAs for Early-Stage GC {#S3.SS3}
----------------------------------------------------------------------------

To investigate whether candidate exosomal miRNAs in serum could be used as a potential biomarker, an independent patient cohort was validated by real-time qRT-PCR. Among the eight candidates, only four miRNAs were found to be potential diagnostic biomarkers for early-stage GC patients. As shown in [Figures 2A--D](#F2){ref-type="fig"}, the ΔCt values of miR-92b-3p, let-7g-5p, miR-146b-5p, and miR-9-5p were significantly lower in early-stage GC patients as compared to healthy individuals (*p* \< 0.05). Meanwhile, serum levels of CEA failed to distinguish early-stage GC patients from healthy individuals (*p* = 0.7329) ([Figure 2E](#F2){ref-type="fig"}). Compared to healthy individuals, the expression levels of miR-92b-3p, let-7g-5p, miR-146b-5p, and miR-9-5p were 2.018, 3.926, 1.784, and 1.266-fold higher, respectively, in early-stage GC patients ([Supplementary Table S2](#DS1){ref-type="supplementary-material"}). We assessed the diagnostic capacity of each miRNA by computing their ROC curve. The results are illustrated in [Figures 3A--D](#F3){ref-type="fig"}. Among the four candidates, let-7g-5p possessed the highest diagnostic power in discriminating early-stage GC patients and healthy individuals with AUC at 0.756 (95% CI, 0.659--0.892, cut-off \< 4.184, sensitivity = 54%, specificity = 88%), followed by miR-92b-3p at 0.714 (95% CI, 0.613--0.815, cut-off \< 1.690, sensitivity = 58%, specificity = 80%), miR-146b-5p at 0.674 (95% CI, 0.569--0.779, cut-off \< 3.784, sensitivity = 46%, specificity = 82%), and miR-9-5p at 0.626 (95% CI, 0.515--0.738, cut-off \< 4.932, sensitivity = 50%, specificity = 84%). In contrast, the AUC value of CEA was 0.520 (95% CI, 0.405--0.635, cut-off \< 1.440, sensitivity = 38%, specificity = 70%) ([Figure 3E](#F3){ref-type="fig"}).

![Comparison of expression of exosomal miRNAs in early-stage GC patients (GC) and healthy individuals (Normal). The scatter plots of the mean ± SD of ΔCt values of miR-92b-3p **(A)**, let-7g-5p **(B)**, miR-146b-5p **(C)**, and miR-9-5p **(D)**, and the mean ± SD of expression levels of serum CEA **(E)** between early-stage GC patients and healthy individuals.](fgene-11-00237-g002){#F2}

![Receiver operating characteristic curves for the serum exosomal miRNAs and CEA to discriminate early-stage gastric cancer patients from healthy individuals. The AUC values of miR-92b-3p **(A)**, let-7g-5p **(B),** miR-146b-5p **(C)**, miR-9-5p **(D)**, and CEA **(E)** were 0.714 (*p* = 0.0002), 0.756 (*p* \< 0.0001), 0.674 (*p* = 0.0028), 0.626 (*p* = 0.0299), and 0.520 (*p* = 0.7329), respectively. AUC, area under the receiver operating characteristic curve; CI, confidence interval.](fgene-11-00237-g003){#F3}

Combining Multiple Biomarkers Enhances the Diagnostic Power for Early-Stage GC {#S3.SS4}
------------------------------------------------------------------------------

We next explored whether combination of the four exosomal miRNAs could be used to better discriminate early-stage GC patients from healthy individuals. As shown in [Table 3](#T3){ref-type="table"}, totally seven combined panels hold stronger diagnostic power than any single exosomal miRNA. The most powerful diagnostic panel consisting of miR-92b-3p and let-7g-5p received a AUC of 0.775, with sensitivity of 64% and specificity of 78%. The most sensitive diagnostic panel was the combination of miR-92b-3p + miR-146b-5p + miR-9-5p (68%), and the combination of miR-146b-5p + miR-9-5p was the most specific panel (88%). Moreover, significant synergistic effect was also found in the combinations of exosomal miRNA panels and traditional biomarkers ([Table 3](#T3){ref-type="table"}). The combined diagnosis of exosomal miR-92b-3p + let-7g-5p + miR-146b-5p + miR-9-5p with CEA had the most powerful efficiency with an AUC up to 0.786. Interestingly, compared with CEA and the exosomal miRNA panels, the combinations of CEA and any exosomal miRNA panel led to a mild loss of sensitivities but dramatically improved specificities. Among the different combined panels, the best specificity in the panel consisting of miR-92b-3p + miR-146b-5p + miR-9-5p + CEA reached 96% with an AUC of 0.758 ([Table 3](#T3){ref-type="table"}). Our results indicated that the exosomal miRNA combination panels and the combination of exosomal miRNAs with CEA could serve as potential predictive markers for the diagnosis of early-stage GC.

###### 

ROC curve analysis on combinations of serum exosomal miRNAs for early-stage gastric cancer.

  miRNA combination                                       AUC     *p*-Value   95% CI         Cut-off   Sensitivity %   Specificity %
  ------------------------------------------------------- ------- ----------- -------------- --------- --------------- ---------------
  miR-92b-3p + let-7g-5p                                  0.775   \<0.0001    0.684--0.866   \>0.484   64              78
  miR-92b-3p + miR-146b-5p                                0.736   \<0.0001    0.638--0.834   \>0.536   60              82
  miR-146b-5p + miR-9-5p                                  0.705   0.0004      0.604--0.806   \>0.607   44              88
  miR-92b-3p + let-7g-5p + miR-146b-5p                    0.774   \<0.0001    0.683--0.865   \>0.534   58              86
  miR-92b-3p + let-7g-5p + miR-9-5p                       0.774   \<0.0001    0.684--0.865   \>0.525   60              82
  miR-92b-3p + miR-146b-5p + miR-9-5p                     0.75    \<0.0001    0.654--0.845   \>0.492   68              74
  miR-92b-3p + let-7g-5p + miR-146b-5p + miR-9-5p         0.773   \<0.0001    0.682--0.864   \>0.526   60              84
  miR-92b-3p + CEA                                        0.722   0.0001      0.622--0.823   \>0.527   60              80
  miR-92b-3p + let-7g-5p + CEA                            0.784   \<0.0001    0.694--0.875   \>0.599   58              90
  miR-92b-3p + miR-146b-5p + CEA                          0.743   \<0.0001    0.645--0.841   \>0.596   56              88
  miR-92b-3p + miR-9-5p + CEA                             0.724   0.0001      0.624--0.824   \>0.533   58              80
  miR-146b-5p + miR-9-5p + CEA                            0.709   0.0003      0.609--0.810   \>0.584   48              90
  miR-92b-3p + let-7g-5p + miR-146b-5p + CEA              0.784   \<0.0001    0.693--0.874   \>0.640   54              94
  miR-92b-3p + let-7g-5p + miR-9-5p + CEA                 0.784   \<0.0001    0.694--0.874   \>0.599   58              90
  miR-92b-3p + miR-146b-5p + miR-9-5p + CEA               0.758   \<0.0001    0.663--0.853   \>0.701   48              96
  miR-92b-3p + let-7g-5p + miR-146b-5p + miR-9-5p + CEA   0.786   \<0.0001    0.695--0.876   \>0.613   58              90

AUC, area under the receiver operating characteristic curve; CI, confidence interval; ROC, receiver operating characteristic.

Correlation of Serum Exosomal MiRNAs With Clinicopathological Features of Early-Stage GC {#S3.SS5}
----------------------------------------------------------------------------------------

Next, we focused on the relationship between the miRNAs and the clinicopathological features of early-stage GC patients. There was no statistical association between miR-92b-3p, let-7g-5p, miR-146b-5p, and miR-9-5p with age, gender, pathological differentiation, and lymph node metastases. However, the level of miR-92b-3p was significantly (*p* = 0.0021) lower in non/poorly cohesive GC patients ([Figure 4A](#F4){ref-type="fig"}), the levels of let-7g-5p and miR-146b-5p were significantly (*p* = 0.0234 and *p* = 0.0126, respectively) lower in non/low nerve infiltration GC patients ([Figures 4B,C](#F4){ref-type="fig"}), and the level of miR146b-5p was significantly (*p* = 0.0089) increased with the increase in tumor invasion depth ([Figure 4D](#F4){ref-type="fig"}). In this dataset, we did not find any statistical correlations between miR-9-5p and nerve infiltration, poorly cohesive, and invasion depth (*p* \> 0.05).

![Relationship between the ΔCt values of exosomal miRNA biomarkers and clinicopathological features of early-stage gastric cancer. Boxplot showing differential ΔCt values of miR-92b-3p between non-poorly cohesive and poorly cohesive GC patients **(A)**, differential ΔCt values of let-7g-5p **(B)** and miR-146b-5p **(C)** between non-nerve infiltration and nerve infiltration gastric cancer patients, and differential ΔCt values of miR-146b-5p between T1 stage and T2 + T3 stage gastric cancer patients **(D)**.](fgene-11-00237-g004){#F4}

Expression of MiRNAs in GC Tissues {#S3.SS6}
----------------------------------

To further clarify the relationship between the identified exosomal miRNA biomarkers and GC, the miRNA expression data derived from 446 GC tissues and 45 normal gastric tissues were downloaded from The Cancer Genome Atlas (TCGA) database.^[1](#footnote1){ref-type="fn"}^ We used DESeq R package (version 1.8.3) to identify differentially expressed miRNAs between the two groups. Compared to normal gastric tissues, the expression levels of miR-92b-3p and miR-146b-5p were significantly upregulated in GC tissues (*p* = 0.0042 and *p* \< 0.0001, respectively), and the expression levels of let-7g-5p and miR-9-5p were significantly downregulated in GC tissues (*p* = 0.0003 and *p* = 0.0026, respectively) ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"}).

Discussion {#S4}
==========

Although treatments for GC have advanced in recent decades, the early diagnosis relies on traditional imaging examinations, biopsy, or serum biomarkers. Due to inherent clinical heterogeneity, early diagnosis continues to be one of the key challenges in GC. As we known, reliable molecular markers play vital roles in detecting cancers, monitoring recurrence, assessing prognosis, and improving effective personalized cancer therapy ([@B34]; [@B28]). Thus, development of a new non-invasive diagnostic method has become critical to improve therapeutic effect. In this study, we demonstrated that a panel of the circulating exosomal miRNAs had higher diagnostic efficacies than traditional biomarker CEA in early-stage GC. Meanwhile, synergistic effects were also found in combining CEA with the exosomal miRNA markers. These results provided evidence for exosomal miRNAs as a new non-invasive diagnostic option for early-stage GC.

Emerging evidence suggests that exosomal miRNAs can serve as potential biomarkers of GC, and are eligible for diagnosis, predicting recurrences, and providing prognostic information. Serum exosomal miR-10b-5p, miR-195-5p, miR-20a-3p, miR-296-5p were identified as novel potential biomarkers for detecting GC ([@B14]). Low levels of plasma exosomal miRNA-101 and miR-23b have been confirmed to be related to poor prognosis in GC patients, and plasma exosomal miR-23b can be used as a minimally invasive predictive biomarker for the recurrence of GC ([@B17]). Additionally, exosomal miR-21 and miR-1225-5p derived from peritoneal lavage fluid could be novel biomarkers for peritoneal dissemination after curative resection of GC ([@B29]). Even though promising advances have been made in using exosomal miRNAs as diagnostic biomarkers for GC in recent years, the GCs involved in the previous studies are composed of both early and advanced stages (stage I to stage IV). Early diagnosis of GC remains a challenge and non-invasive evidence on diagnosis of early-stage GC is lacking. Hence, reliable biomarkers with high sensitivity and specificity need to be developed. To the best of our knowledge, this is the first study involved only early-stage patients (stage I and stage II) to analysis the early diagnostic value of serum exosomal miRNAs in GC.

MiR-92b-3p has been confirmed to play an important role in cancer proliferation, invasion, and migration. As an oncogenic miRNA, miR-92b-3p promotes carcinogenesis and metastasis by down-regulating F-box and WD-40 domain protein 7 (FBXW7/hCdc4) in colorectal cancer ([@B8]). In accordance with this evidence, we found that up-regulated miR-92b-3p was associated with early-stage GC. Besides, let-7g-5p has been investigated in melanoma, lung adenocarcinoma, ovarian cancer, glioblastoma, and renal cell carcinoma (RCC) ([@B9]; [@B23]). Overexpression of let-7g-5p significantly inhibits cell proliferation and migration, and could be a biomarker of post-operative recurrence and prognosis ([@B23]). Let-7g-5p was clustered into the let-7g family. Down-regulated let-7g has been associated with poor survival and lymph node metastasis in GC ([@B30]). However, the role of let-7g-5p in GC had not been explored. This is the first study to confirm that aberrant expression of serum exosomal let-7g-5p was associated with early-stage GC. Consistent with our data, miR-146b-5p was observed to be up-regulated in colorectal cancer and renal cell carcinoma ([@B36]), but frequently down-regulated in pancreatic cancer and glioblastoma ([@B19]). Recent studies showed that deregulation of miR-146b-5p in GC tissue was associated with the tumor stage, and could be used as a prognosis biomarker ([@B33]). In this study, we further verified the diagnostic role of serum exosomal miR-146b-5p in early-stage GC. Moreover, we found that serum exosomal miR-9-5p was up-regulated in early-stage GC. Likewise, up-regulation of miR-9-5p was observed in both breast cancer and lung cancer, which promoted tumor proliferation, invasion, and metastasis ([@B1]). However, functional roles of miR-146b-5p and miR-9-5p in GC remain unknown.

It is of note that the molecular profile of tumors dynamically changes among patients as well as over time. In terms of miRNA profile, the expression signatures are also significantly varies as the medical condition of the specific donor differs. Among the biomarkers for early diagnosis of GC, the levels of miR-92b in plasma and miR-146b-5p in tissue have also been found significantly different between early- and late-stage GC ([@B6]; [@B35]). Additionally, differential expression of let-7g-5p in tissue has been found between early- and late-stage clear cell renal carcinoma ([@B9]). However, the evidences for the differential expression of miR-9-5p and let-7g-5p between early- and late-stage GC are still lacking. These phenomena suggest the exosomal miRNA biomarkers for early diagnosis of cancer are not necessarily aberrantly expressed throughout the process of GC.

It has been reported that different expression levels of miRNAs could be frequently observed between circulating and tissue samples ([@B31]; [@B13]). In our study, based on TCGA data, we found that miR-92b-3p and miR-146b-5p were significantly upregulated in GC tissues, while let-7g-5p and miR-9-5p were significantly downregulated in GC tissues. We suspected that the discrepancies of the expression signatures between tissues and serum exosomes might be due to the following explanations. First, the absorption and degradation efficiency of circulating exosomal miRNAs and tissue miRNAs are quite different, and varieties in techniques and sequencing platform might also contribute to the discrepancies ([@B24]). Second, compared with circulating exosomal miRNA reflecting the systematic disease status of GC, tissue miRNAs just presented the landscape of local changes. Currently, although significant advances have been achieved in exosome study, the understanding of the packaging and releasing mechanism of circulating exosomal miRNAs is still far from complete. Intensive work is still required to clarify the relationship of miRNAs between circulating exosomes and tissues.

In this study, combination of serum CEA and a panel of serum exosomal miRNAs (miR-92b-3p + let-7g-5p + miR-146b-5p + miR-9-5p) reached the highest diagnostic power for early stage GC, which could relieve a substantial proportion of patients from invasive biopsy. Nonetheless, this study had several potential limitations. First, although the results successfully showed four GC-related exosomal miRNAs, the number of early-stage GC patients enrolled in the study was limited. Further studies are necessary to evaluate these exosomal miRNA signatures in a larger cohort of early-stage GC patients. Second, the heterogeneous patient population could impact overall accuracy of the exosomal miRNAs, and our future study will compare the exosomal miRNAs with diverse tumor types. Third, we cannot elucidate the origin of the diagnostic miRNA markers. Whether they are derived from GC cells requires further investigation.

Conclusion {#S5}
==========

This study demonstrated the diagnostic values of serum exosomal miR-92b-3p, -146b-5p, -9-5p, and let-7g-5p in early-stage GC, and suggested the possibility of non-invasive circulating exosomal miRNAs as an alternative to conventional invasive approaches in detection of GC in the future. Moreover, large-scale validation is still required to confirm the potential applicability of these markers in GC diagnosis.

Data Availability Statement {#S6}
===========================

The raw sequencing data for this study can be found in the Gene Expression Omnibus database (accession number: [GSE130654](GSE130654)).

Ethics Statement {#S7}
================

The studies involving human participants were reviewed and approved by the Harbin Medical University Cancer Hospital Ethics Committee. The patients/participants provided their written informed consent to participate in this study.

Author Contributions {#S8}
====================

ST, YZ, and XH conceived and designed the study. ST and JC performed the experiments. YY and CL collected the samples and organized the clinical information. LW was responsible for the data processing and analysis of next-generation sequencing. ST performed statistical analysis and wrote the manuscript. YY, YZ, and XH reviewed and edited the manuscript. All the authors read and approved the final manuscript.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by the National Natural Science Foundation of China (grant numbers 81872427, 81672428, 81703000, and 81572528); Outstanding Youth Fund of Heilongjiang Province (grant number JC2018024); Sister Institution Network Fund (SINF) of MD Anderson (grant number 201402); and the Haiyan Fund Project of Harbin Medical University Cancer Hospital (grant number JJQN2019-02).

[cancergenome.nih.gov/](http://www.cancergenome.nih.gov/)

Supplementary Material {#S10}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fgene.2020.00237/full#supplementary-material>

###### 

Click here for additional data file.

###### 

Click here for additional data file.

[^1]: Edited by: Meng Zhou, Wenzhou Medical University, China

[^2]: Reviewed by: Ya Cui, University of California, Irvine, United States; Guangchao Yang, City of Hope National Medical Center, United States

[^3]: ^†^These authors have contributed equally to this work

[^4]: This article was submitted to Bioinformatics and Computational Biology, a section of the journal Frontiers in Genetics
